PD-L1 protein degradation that occurs in proteasomes or lysosomes could use multiple pathways of degradation, leading to enriched immunotherapy strategies for cancer, and providing a potential strategy to increase the response rates of PD-1/PD-L1 blockade in cancer immunotherapy [40]. The gene discussed is PDCD1; the disease is cancer.